Upcoming Dividend • Jun 16
Upcoming dividend of CN¥0.69 per share Eligible shareholders must have bought the stock before 23 June 2026. Payment date: 18 August 2026. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 4.7%. Within top quartile of German dividend payers (4.6%). Higher than average of industry peers (3.1%). Declared Dividend • May 20
Dividend of CN¥0.69 announced Shareholders will receive a dividend of CN¥0.69. Ex-date: 23rd June 2026 Payment date: 18th August 2026 Dividend yield will be 36%, which is higher than the industry average of 3.3%. Sustainability & Growth Dividend is well covered by both earnings (30% earnings payout ratio) and cash flows (15% cash payout ratio). The dividend has increased by an average of 8.3% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 32% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • Apr 10
Sinopharm Group Co. Ltd. to Report Q1, 2026 Results on Apr 24, 2026 Sinopharm Group Co. Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026 Announcement • Mar 23
Sinopharm Group Co. Ltd., Annual General Meeting, Jun 18, 2026 Sinopharm Group Co. Ltd., Annual General Meeting, Jun 18, 2026. Announcement • Mar 10
Sinopharm Group Co. Ltd. to Report Fiscal Year 2025 Results on Mar 20, 2026 Sinopharm Group Co. Ltd. announced that they will report fiscal year 2025 results on Mar 20, 2026 Announcement • Nov 28
Sinopharm Group Co. Ltd. Announces Board and Committee Resignations The board of directors of Sinopharm Group Co. Ltd. announced that on 28 November 2025, due to the work arrangement, Mr. Zhao Bingxiang ("Mr. Zhao") tendered his resignation to the Board as a non-executive Director, the chairman (the "Chairman") of the Board, the chairman of the nomination committee of the Board (the "Nomination Committee"), the chairman of the strategy and investment committee of the Board (the "Strategy and Investment Committee"), a member of the legal and compliance and environmental, social and governance committee of the Board (the "Legal and Compliance and Environmental, Social and Governance Committee") and the authorized representative (the "Authorized Representative") of
the Company (pursuant to Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules")), and Ms. Feng Rongli ("Ms. Feng") tendered her resignation to the Board as a non-executive Director, a member of the remuneration committee of the Board and a member of the Nomination Committee. Each of the above resignations shall take effect from the appointment of their respective replacement at the general meeting of the Company. Announcement • Oct 10
Sinopharm Group Co. Ltd. to Report Nine Months, 2025 Results on Oct 24, 2025 Sinopharm Group Co. Ltd. announced that they will report nine months, 2025 results on Oct 24, 2025 Announcement • Aug 12
Sinopharm Group Co. Ltd. to Report First Half, 2025 Results on Aug 22, 2025 Sinopharm Group Co. Ltd. announced that they will report first half, 2025 results on Aug 22, 2025 Announcement • Apr 10
Sinopharm Group Co. Ltd. to Report Q1, 2025 Results on Apr 25, 2025 Sinopharm Group Co. Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025 Announcement • Mar 12
Sinopharm Group Co. Ltd. to Report Fiscal Year 2024 Results on Mar 21, 2025 Sinopharm Group Co. Ltd. announced that they will report fiscal year 2024 results on Mar 21, 2025 Announcement • Feb 12
Sinopharm Group Co. Ltd. Approves Board Appointments Sinopharm Group Co. Ltd. announced at its EGM held on February 12, 2025, the shareholders approved appointment of Mr. Sun Jinglin as an executive Director of the sixth session of the Board; Mr. Hu Ligang as a non-executive Director of the sixth session of the Board; Mr. Zu Jing as a non-executive Director of the sixth session of the Board; and Mr. Xing Yonggang as a non-executive Director of the sixth session of the Board. Announcement • Jan 08
Sinopharm Group Co. Ltd. Announces Board Resignations Sinopharm Group Co. Ltd. announced that, due to work needs, Mr. Wang Kan and Mr. Wang Peng have tendered their resignation as non-executive directors to the board on 8 January 2025. The resignations will take immediate effect. New Risk • Nov 13
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 43% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. This is currently the only risk that has been identified for the company. Reported Earnings • Oct 28
Third quarter 2024 earnings released: EPS: CN¥0.50 (vs CN¥0.64 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.50 (down from CN¥0.64 in 3Q 2023). Revenue: CN¥147.7b (up 1.9% from 3Q 2023). Net income: CN¥1.57b (down 21% from 3Q 2023). Profit margin: 1.1% (down from 1.4% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year whereas the company’s share price has increased by 5% per year. Announcement • Oct 14
Sinopharm Group Co. Ltd. to Report Nine Months, 2024 Results on Oct 25, 2024 Sinopharm Group Co. Ltd. announced that they will report nine months, 2024 results on Oct 25, 2024 Valuation Update With 7 Day Price Move • Oct 02
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €2.36, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 14x in the Healthcare industry in Germany. Total returns to shareholders of 21% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €4.52 per share. New Risk • Sep 25
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 43% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. This is currently the only risk that has been identified for the company. Reported Earnings • Sep 25
Second quarter 2024 earnings released Second quarter 2024 results: Net loss: CN¥1.42b (down 156% from profit in 2Q 2023). Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Announcement • Aug 28
Sinopharm Group Co. Ltd. Announces Change in President The Board of Sinopharm Group Co. Ltd. announced that it resolved to appoint Mr. Lian Wanyong as the President of the Company on 27 August 2024 with immediate effect. Mr. Liu Yong ("Mr. Liu") ceased to be the President. The above arrangements took effect immediately. Mr. Lian Wanyong, aged 53, holds a master's degree in medicine from Zhongshan Medical Sciences University and a master's degree in business administration from the University of Miami and is an associate chief pharmacist. Mr. Lian successively served as the deputy director of the financial assets management department, a director of the investment management department and the deputy director of policy research office of China National Pharmaceutical Group Co. Ltd. Mr. Lian successively served as a Director and supervisor of the Company from December 2008 to January 2018, and served as a vice president and a member of Party Committee of the Company, a director of China National Accord Medicines Corporation Ltd. and a director of China National Medicines Corporation Ltd. from January 2018 to September 2022. Mr. Lian served as a director, the president and the deputy secretary of Party Committee of Shanghai Shyndec Pharmaceutical Co. Ltd. from September 2022 to August 2024. Announcement • Aug 27
Sinopharm Group Co. Ltd. Announces Management Changes The board of directors of Sinopharm Group Co. Ltd. announced that it resolved to propose to appoint Mr. Zhao Bingxiang ("Mr. Zhao") as the non-executive Director and Mr. Lian Wanyong ("Mr. Lian") as the executive Director
(the "Proposed Appointment of Directors") on 27 August 2024. In accordance with the articles of association of the Company (the "Articles of Association"), the above Proposed Appointment of Directors are subject to the approval by the shareholders of the Company (the "Shareholders") at the extraordinary general meeting of the Company. The Board hereby announces that it resolved to appoint Mr. Lian Wanyong as the President of the Company on 27 August 2024 with immediate effect. The Board hereby announces that on 27 August 2024, due to work needs, Mr. Yu Qingming ("Mr. Yu") ceased to be the Chairman of the Board, an executive Director as well as the chairman of the Nomination Committee, the chairman of the strategy and investment committee of the Board (the "Strategy and Investment Committee") and a member of the legal and compliance and environmental, social and governance committee of the Board (the "Legal and Compliance and Environmental, Social and Governance Committee"); Mr. Liu Yong ("Mr. Liu") ceased to be an executive Director, the President and a member of the Strategy and Investment Committee and a member of the Legal and Compliance and Environmental, Social and Governance Committee. The
above arrangements took effect immediately. China National Pharmaceutical Group Co. Ltd. will make other appointments for Mr. Yu and Mr. Liu. Mr. Lian Wanyong, aged 53, holds a master's degree in medicine from Zhongshan Medical Sciences University and a master's degree in business administration from the University of Miami and is an associate chief pharmacist. Mr. Lian successively served as the deputy director of the financial assets
management department, a director of the investment management department and the deputy director of policy research office of China National Pharmaceutical Group Co. Ltd. Mr. Lian successively served as a Director and supervisor of the Company from December 2008 to January 2018, and served as a vice president and a member of Party Committee of the Company, a director of China National Accord Medicines Corporation Ltd. and a director of China National Medicines Corporation Ltd. from January 2018 to September 2022. Mr. Lian served as a director, the president and the deputy secretary of Party Committee of Shanghai Shyndec Pharmaceutical Co. Ltd. from September 2022 to August 2024. Reported Earnings • Aug 25
Second quarter 2024 earnings released Second quarter 2024 results: Net loss: CN¥419.6m (down 117% from profit in 2Q 2023). Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Announcement • Aug 09
Sinopharm Group Co. Ltd. to Report First Half, 2024 Results on Aug 23, 2024 Sinopharm Group Co. Ltd. announced that they will report first half, 2024 results on Aug 23, 2024 Announcement • Jun 14
Sinopharm Group Co. Ltd. Declares Final Dividend for the Fiscal Year Ended December 31, 2023, Payable on 13 August 2024 Sinopharm Group Co. Ltd. declared final dividend of RMB 0.87 per share for the fiscal year ended December 31, 2023. Ex-dividend date is 17 June 2024. Record date is 24 June 2024Payment date is 13 August 2024. Upcoming Dividend • Jun 10
Upcoming dividend of CN¥0.87 per share Eligible shareholders must have bought the stock before 17 June 2024. Payment date: 13 August 2024. Payout ratio is a comfortable 31% and this is well supported by cash flows. Trailing yield: 3.9%. Lower than top quartile of German dividend payers (4.6%). Higher than average of industry peers (2.9%). Reported Earnings • Apr 28
Full year 2023 earnings released: EPS: CN¥2.91 (vs CN¥2.74 in FY 2022) Full year 2023 results: EPS: CN¥2.91 (up from CN¥2.74 in FY 2022). Revenue: CN¥596.6b (up 8.0% from FY 2022). Net income: CN¥9.05b (up 6.2% from FY 2022). Profit margin: 1.5% (in line with FY 2022). Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Announcement • Apr 17
Sinopharm Group Co. Ltd. to Report Q1, 2024 Results on Apr 26, 2024 Sinopharm Group Co. Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024 Declared Dividend • Mar 27
Dividend of CN¥0.87 announced Shareholders will receive a dividend of CN¥0.87. Ex-date: 17th June 2024 Payment date: 13th August 2024 Dividend yield will be 37%, which is higher than the industry average of 3.3%. Sustainability & Growth Dividend is well covered by both earnings (30% earnings payout ratio) and cash flows (18% cash payout ratio). The dividend has increased by an average of 13% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 20% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Mar 25
Full year 2023 earnings released: EPS: CN¥2.91 (vs CN¥2.73 in FY 2022) Full year 2023 results: EPS: CN¥2.91 (up from CN¥2.73 in FY 2022). Revenue: CN¥596.6b (up 8.0% from FY 2022). Net income: CN¥9.05b (up 6.2% from FY 2022). Profit margin: 1.5% (in line with FY 2022). Revenue is forecast to grow 7.6% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 5% per year. Announcement • Mar 13
Sinopharm Group Co. Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024 Sinopharm Group Co. Ltd. announced that they will report fiscal year 2023 results on Mar 22, 2024 Valuation Update With 7 Day Price Move • Jan 29
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €2.35, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 16x in the Healthcare industry in Germany. Total returns to shareholders of 27% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €3.51 per share. Reported Earnings • Oct 31
Third quarter 2023 earnings released: EPS: CN¥0.64 (vs CN¥0.70 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.64 (down from CN¥0.70 in 3Q 2022). Revenue: CN¥145.0b (flat on 3Q 2022). Net income: CN¥1.99b (down 7.9% from 3Q 2022). Profit margin: 1.4% (in line with 3Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 5% per year. Announcement • Oct 14
Sinopharm Group Co. Ltd. to Report Nine Months, 2023 Results on Oct 27, 2023 Sinopharm Group Co. Ltd. announced that they will report nine months, 2023 results on Oct 27, 2023 Announcement • Sep 16
Sinopharm Group Co. Ltd. Approves Appointment of Guo Jinhong as Chief Supervisor Sinopharm Group Co. Ltd. at its EGM held on September 15, 2023, considered and approved (if thought fit) the appointment of Mr. Guo Jinhong as a shareholder representative Supervisor of the sixth session of the Supervisory Committee, to authorize the Supervisory Committee to determine his remuneration and to authorize the chairman of the Board or any executive Director to enter into the service contract or such other documents or supplemental agreements or deeds with him. The Board also announced that the sixth session of the Supervisory Committee comprises five Supervisors, and the independent Supervisors are Ms. Guan Xiaohui and Mr. Liu Zhengdong, shareholderrepresentative Supervisor is Mr. Guo Jinhong and the employee representative Supervisors are Mr. Liu Hongbing and Ms. Lu Haiqing. The first meeting of the sixth session of the Supervisory Committee was held on 15 September 2023 and resolved to elect Ms. Guan Xiaohui as the chief Supervisor of the Supervisory Committee. Announcement • Aug 29
Sinopharm Group Co. Ltd. Announces Retirement of Ma Ping, A Non-Executive Director Sinopharm Group Co. Ltd. announced meanwhile, in view of the retirement of Mr. Ma Ping, a non-executive Director, the Board resolved at the same meeting to propose to appoint Mr. Wang Peng as a non-executive Director of the sixth session of the Board. The Board resolved at the meeting of the Board held on 25 August 2023 to elect Mr. Shi Shenghao, an independent non-executive Director, as a member of the strategy and investment committee of the Board, with immediate effect. Mr. Ma Ping, a non-executive Director of the fifth session of the Board, will retire upon the approval of appointment of Directors of the sixth session of the Board at the extraordinary general meeting of the Company. Mr. Ma Ping has confirmed that he has no disagreement with the Board, and there is no other matters relating to his resignation as a Director that needs to be brought to the attention of the shareholders (the "Shareholders") and creditors of the Company. The Board would like to take this opportunity to express its sincere gratitude to Mr. Ma Ping for his contributions to the Company during his tenure as a Director. The Board resolved at the meeting of the Board held on 25 August 2023 to elect Mr. Shi Shenghao, an independent non-executive Director, as a member of the strategy and investment committee of the Board, with immediate effect. Reported Earnings • Aug 28
Second quarter 2023 earnings released: EPS: CN¥0.81 (vs CN¥0.72 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.81 (up from CN¥0.72 in 2Q 2022). Revenue: CN¥155.4b (up 16% from 2Q 2022). Net income: CN¥2.51b (up 11% from 2Q 2022). Profit margin: 1.6% (down from 1.7% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year and the company’s share price has also increased by 9% per year. Announcement • Aug 16
Sinopharm Group Co. Ltd. to Report First Half, 2023 Results on Aug 25, 2023 Sinopharm Group Co. Ltd. announced that they will report first half, 2023 results on Aug 25, 2023 Valuation Update With 7 Day Price Move • Aug 08
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to €2.40, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 18x in the Healthcare industry in Germany. Total returns to shareholders of 30% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €2.05 per share. Upcoming Dividend • Jun 12
Upcoming dividend of CN¥0.82 per share at 3.4% yield Eligible shareholders must have bought the stock before 19 June 2023. Payment date: 14 August 2023. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 3.4%. Lower than top quartile of German dividend payers (4.7%). In line with average of industry peers (3.2%). Announcement • May 19
Sinopharm Group Co. Ltd. Announces Resignation of Zhuo Fumin as Independent Non-Executive Director Sinopharm Group Co. Ltd. (the Company) announced that on 18 May 2023, due to attainment of the term of service of independent non-executive Directors as stipulated in the Rules of Procedure of Board of Directors of the Company, Mr. Zhuo Fumin (Mr. Zhuo) tendered his resignation as an independent non-executive Director of the Company, a member of the audit committee of the Board (the Audit Committee), and a member of the nomination committee of the Board (the Nomination Committee), which shall take effect from the appointment of his replacement at the general meeting of the Company. Mr. Zhuo has confirmed that he has no disagreement with the Board and there is no other matters relating to his resignation as a Director that needs to be brought to the attention of the shareholders of the Company (the Shareholders) and creditors of the Company. Reported Earnings • Mar 29
Full year 2022 earnings released: EPS: CN¥2.73 (vs CN¥2.49 in FY 2021) Full year 2022 results: EPS: CN¥2.73 (up from CN¥2.49 in FY 2021). Revenue: CN¥552.1b (up 6.0% from FY 2021). Net income: CN¥8.53b (up 9.9% from FY 2021). Profit margin: 1.5% (in line with FY 2021). Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 10% per year. Reported Earnings • Oct 28
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: CN¥144.9b (up 9.6% from 3Q 2021). Net income: CN¥2.16b (up 2.1% from 3Q 2021). Profit margin: 1.5% (down from 1.6% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Germany. Reported Earnings • Aug 30
Second quarter 2022 earnings released Second quarter 2022 results: Net income: CN¥2.27b (up CN¥2.27b from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Upcoming Dividend • Jun 20
Upcoming dividend of CN¥0.75 per share Eligible shareholders must have bought the stock before 27 June 2022. Payment date: 23 August 2022. Payout ratio is a comfortable 29% and this is well supported by cash flows. Trailing yield: 4.7%. Within top quartile of German dividend payers (4.5%). Higher than average of industry peers (3.0%). Reported Earnings • Apr 28
Full year 2021 earnings released: EPS: CN¥2.49 (vs CN¥2.31 in FY 2020) Full year 2021 results: EPS: CN¥2.49 (up from CN¥2.31 in FY 2020). Revenue: CN¥521.1b (up 14% from FY 2020). Net income: CN¥7.76b (up 8.0% from FY 2020). Profit margin: 1.5% (down from 1.6% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 11%, compared to a 5.7% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Reported Earnings • Oct 27
Third quarter 2021 earnings released: EPS CN¥0.68 (vs CN¥0.75 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: CN¥132.2b (up 6.7% from 3Q 2020). Net income: CN¥2.12b (up 2.7% from 3Q 2020). Profit margin: 1.6% (down from 1.7% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Executive Departure • Jun 14
Independent Chief Supervisor Yifang Wu has left the company On the 10th of June, Yifang Wu's tenure as Independent Chief Supervisor ended after less than a year in the role. We don't have any record of a personal shareholding under Yifang's name. A total of 8 executives have left over the last 12 months. The current median tenure of the management team is 2.96 years. Upcoming Dividend • Jun 08
Upcoming dividend of CN¥0.69 per share Eligible shareholders must have bought the stock before 15 June 2021. Payment date: 10 August 2021. Trailing yield: 3.0%. Lower than top quartile of German dividend payers (3.2%). Higher than average of industry peers (2.1%). Executive Departure • Apr 29
Joint Company Secretary has left the company On the 27th of April, Wei Liu's tenure as Joint Company Secretary ended after 9.7 years in the role. We don't have any record of a personal shareholding under Wei's name. A total of 3 executives have left over the last 12 months. Reported Earnings • Apr 25
Full year 2020 earnings released: EPS CN¥2.31 (vs CN¥2.11 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥456.4b (up 7.3% from FY 2019). Net income: CN¥7.19b (up 15% from FY 2019). Profit margin: 1.6% (up from 1.5% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 23
Full year 2020 earnings released The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥456.4b (up 7.3% from FY 2019). Net income: CN¥7.19b (up 15% from FY 2019). Profit margin: 1.6% (up from 1.5% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Nov 26
New 90-day high: €2.20 The company is up 6.0% from its price of €2.08 on 27 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €4.35 per share. Reported Earnings • Oct 24
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥6.61b, up 7.9% from the prior year. Total revenue was CN¥440.2b over the last 12 months, up 8.3% from the prior year. Is New 90 Day High Low • Oct 15
New 90-day low: €1.81 The company is down 14% from its price of €2.10 on 17 July 2020. The German market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.61 per share. Announcement • Oct 13
Sinopharm Group Co., Ltd. to Report Nine Months, 2020 Results on Oct 22, 2020 Sinopharm Group Co., Ltd. announced that they will report nine months, 2020 results on Oct 22, 2020 Is New 90 Day High Low • Sep 25
New 90-day low: €1.84 The company is down 19% from its price of €2.26 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is down 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.60 per share. Announcement • Sep 20
Sinopharm Group Co., Ltd. Appoints Management Team The board of directors of Sinopharm Group Co. Ltd. announced that the first meeting of the fifth session of the Board resolved on 18 September 2020 to elect Chairman and Vice Chairman of the Board of the Company, and to appoint members and chairman of the special committees under the Board. In addition, the first meeting of the fifth session of the supervisory commit ee of the Company resolved on 18 September 2020 to elect the Chief Supervisor of the Supervisory Committee. The details are as follows: The Board resolved to elect Mr. Li Zhiming as the Chairman of the Board and Mr. Chen Qiyu as the Vice Chairman of the Board. Reported Earnings • Sep 19
First half earnings released Over the last 12 months the company has reported total profits of CN¥6.17b, up 2.6% from the prior year. Total revenue was CN¥427.4b over the last 12 months, up 12% from the prior year. Announcement • Aug 10
Sinopharm Group Co., Ltd. to Report Q2, 2020 Results on Aug 21, 2020 Sinopharm Group Co., Ltd. announced that they will report Q2, 2020 results on Aug 21, 2020 
